EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models

H.R. Hendriks, P.E. Pizao, D.P. Berger, K.L. Kooistra, M.C. Bibby, E. Boven, H.C. Dreef-Van der Meulen, R.E.C. Henrar, H.H. Fiebig, J.A. Double, H.W. Hornstra, H.M. Pinedo, P. Workman, G. Schwartsmann

Research output: Contribution to journalArticleAcademicpeer-review

97 Downloads (Pure)
Original languageEnglish
Pages (from-to)897-906
JournalEuropean Journal of Cancer
Issue number6
Publication statusPublished - 1993

Cite this